An Overview of the Biochemical Causes of Dementia Including Neurotransmitters and Hormones, with Potential Treatments Discussed
DOI:
https://doi.org/10.58445/rars.3250Keywords:
Dementia, Neurodegenerative disorders, Alzheimer’s disease (AD), Vascular dementia (VD)Abstract
Dementia is a series of chronic, incurable neurodegenerative disorders which all commonly result in progressive psychological deterioration and eventually death. Presently, over 70 variations of dementia have been documented. This review paper covers the role of neurotransmitters (NTs) and hormones in the development/severity of the 5 most common variations of dementia: Alzheimer’s Disease (AD), Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Vascular Dementia (VD), and Parkinson’s Disease (PD). NTs have proven to be crucial in maintaining neuroplasticity and basic cognitive functions. Hormones have shown their importance in long-term neurocognitive development and several biochemical regulation processes that maintain the brain’s metabolism. There are several potential treatments for these variations of dementia, mainly based on NT and/or hormone level regulation therapy. A treatment strategy which combines and interchangeably utilizes NT and hormone level regulation therapy is also proposed. The goal of this review paper is to show that the main causes of dementia may be hiding in plain sight, and that with an optimistic mindset, a universal cure can be developed.
References
Akhter, F., Persaud, A., Zaokari, Y., Zhao, Z., & Zhu, D. (2021). Vascular dementia and
underlying sex differences. Frontiers in Aging Neuroscience.
https://pubmed.ncbi.nlm.nih.gov
Alzheimer Society of Canada. (n.d.). Every person is different with Lewy.
In Lewy Body Dementia Canada.
Bondi, M. W. (2017). Alzheimer’s disease: Past, present, and future. PMC.
Engelhardt, E. (n.d.). Alois Alzheimer and vascular brain disease: Arteriosclerotic atrophy of the
brain. PMC.
Vejandla, B., Savani, S., Appalaneni, R., et al. (2024, January 5). Alzheimer’s disease: The past,
present, and future of a globally progressive disease. Cureus, 16(1), e51705.
https://doi.org/10.7759/cureus.51705
Buffington, A. L. H., Lipski, D. M., & Westfall, E. (2013). Dementia: An evidence-based review of
common presentations and family-based interventions. Journal of Osteopathic Medicine,
(10), 768–775.
https://doi.org/10.7556/jaoa.2013.046
Cramb, K. M. L., et al. (2023). Impaired dopamine release in Parkinson’s disease. Brain.
https://pubmed.ncbi.nlm.nih.gov
Flores-Cordero, J. A., Pérez-Pérez, A., Jiménez-Cortegana, C., et al. (2022). Obesity as a risk
factor for dementia and Alzheimer’s disease: The role of leptin. International Journal of
Molecular Sciences, 23(9), 5202.
https://doi.org/10.3390/ijms23095202
Huber, N., Korhonen, S., Hoffmann, D., Leskelä, S., Rostalski, H., & Haapasalo, A. (2022).
Neurotransmitter deficits from frontotemporal lobar degeneration. Molecular Psychiatry.
https://doi.org/10.1038/s41380-021-01349-3
Huey, E. D., Putnam, K. T., & Grafman, J. (2006). A systematic review of neurotransmitter
deficits and treatments in frontotemporal dementia. Neurology, 66(1), 17–22.
https://doi.org/10.1212/01.wnl.0000191304.55104.3d
Jawaid, A., Rademakers, R., Kass, J. S., Kalkonde, Y., & Schulz, P. E. (2009). Traumatic brain
injury may increase the risk for frontotemporal dementia through reduced progranulin.
Neurodegenerative Diseases, 6(5–6), 219–220.
https://doi.org/10.1159/000258704
Lin, L., et al. (2013). Melatonin in Alzheimer’s disease. Journal of Pineal Research.
Murley, A. G., & Rowe, J. B. (2018). Neurotransmitter deficits from frontotemporal lobar
degeneration. Brain, 141(5), 1263–1285.
https://doi.org/10.1093/brain/awy072
Nitrini, R. (2023). The past, present and future of Alzheimer’s disease – Part 1. PMC.
Stárka, L. (n.d.). What is a hormone? PMC.
Teleanu, R. I. (2022). Neurotransmitters—Key factors in neurological and neurodegenerative
disorders of the central nervous system. PMC.
Wang, J., Zhang, Y., Tian, N., Ya, D., Jiawen, W., et al. (2024). Mechanisms of glutamate
metabolic function and dysfunction in vascular dementia. Neuroprotection.
https://onlinelibrary.wiley.com
Wang, R., & Reddy, P. H. (2017). Role of glutamate and NMDA receptors in Alzheimer’s
disease. Journal of Alzheimer’s Disease, 57(4), 1041–1048.
Downloads
Posted
Categories
License
Copyright (c) 2025 Aniketh Sadanala
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
